New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy — BioPortfolio.com

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy — BioPortfolio.com: From BioPortfolio: SALT LAKE CITY, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that...

Comments

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News